To investigate a possible influence of GB virus C (GBV-C) in immunocompromised patients, the prevalences of GBV-C RNA and anti -E2 antibody in 197 human immunodeficiency virus (HIV) -infected patients and in 120 control blood donors were studied. GBV-C RNA was detected in 33 of 197 HIV-infected patients (16.8%) compared with 1 in 120 blood donors (0.8%) (P õ .001). Previous exposure to GBV-C (anti -E2 antibody -positive) was shown in 56.8% of HIV patients and in 9% of blood donors. GBV-C viremia was not associated with hepatitis. Despite approximately equal duration of HIV infection in all subgroups, the CD4 cell counts were significantly higher in GBV-C -viremic patients (344 cells/mL) compared with exposed (259 cells/mL) and unexposed (170 cells/mL) patients (P Å .017 and P õ .001). Furthermore, Kaplan-Meier analysis demonstrated significantly better cumulative survival in GBV-C RNA -positive HIV-infected patients, suggesting that GBV-C might be a favorable prognostic factor in HIV disease. uncertain [4, [6] [7] [8] . However, no data are available, to our knowl- ized at 15ЊC for 10 min to an internal GBV-C-specific oligonucleotide probe. Sequences of sense and antisense primers and the
the flaviviridae family, GB virus C (GBV-C) and hepatitis G virus

Serologic studies for the detection of HIV, HBV, and HCV.
(HGV), were identified in human sera, some from patients with HIV antibodies were detected using an ELISA (Abbott Laboracryptogenic or posttransfusion hepatitis [3, 4] . GBV-C and HGV tories, Abbott Park, IL). Positive ELISA results were confirmed by are closely related isolates of the same virus, with ú95% sequence Western blot. All participants were tested for anti-HCV antibodies homology [5] . Although the new virus was detected in patients (Abbott 2nd generation test), and positive sera were also tested with various forms of liver disease, its wide distribution among uncertain [4, [6] [7] [8] . However, no data are available, to our knowl- Therefore, we retrospectively studied the seroprevalences of Detection of GBV-C RNA. RNA extracted from the equivalent GBV-C RNA and anti-E2 antibodies in HIV-infected patients of 5 mL of serum was amplified in a single-tube RT-PCR as and correlated the results with the clinical follow-up data of the previously described [11] . Briefly, cDNA synthesis was performed patients. The anti-E2 antibody is directed against the envelope at 60ЊC for 30 min using rTth polymerase (Roche Molecular Sys-2 protein of GBV-C and was recently demonstrated to indicate tems, Branchburg, NJ) and a gene-specific antisense primer, folexposure to the virus. Its appearance is mostly associated with lowed by 35 cycles of amplification in a two-temperature PCR viral clearance (GBV-C RNA-negative by reverse transcriptaseprotocol (94ЊC for 40 s, 63ЊC for 60 s). PCR products were hybridpolymerase chain reaction [RT-PCR]) [9, 10] .
ized at 15ЊC for 10 min to an internal GBV-C-specific oligonucleotide probe. Sequences of sense and antisense primers and the
Patients and Methods
hybridization probe were deduced from the 5 untranslated region of GBV-C [11] . PCR amplicon-probe complexes were specifically We enrolled 197 HIV-infected patients who regularly attended detected by a microparticle capture EIA (Abbott Laboratories). our outpatient clinic between January 1993 and December 1994.
Two dilutions of a GBV-C-positive serum served as a positive control, and a GBV-C-negative serum served as a negative control. investigated by strand-specific reverse transcription followed blood donors were positive for the anti -E2 antibody (P õ by RNase H digestion and nested PCR of the 5 untranslated .001). None of the antibody-positive patients had detectable region. Only positive-(not negative-) strand GBV-C RNA was GBV-C RNA levels. Only 52 of 197 HIV patients (26.4%) had detected in all 3 samples. no markers of GBV-C infection. With respect to GBV-C status, Survival analysis. For this analysis, we calculated the pewe differentiated viremic (GBV-C RNA -positive), exposed riod from the first positive HIV test, available for 179 of 197 (anti -E2 antibody -positive/GBV-C RNA -negative), and unpatients, to a cutoff date or death, because the exact date of exposed (anti -E2 antibody -negative/GBV-C RNA -negative) HIV seroconversion was not known. Follow-up data for 28 HIV-infected patients.
GBV-C RNA -positive patients, 104 anti -E2 antibody -posiTransmission risk factors for an infection with GBV-C were tive patients, and 47 patients without exposure to GBV-C rededuced from the viral prevalence in the HIV risk groups.
vealed that HIV infection was of approximately equal duration Intravenous drug use (51.5%) and homosexuality (39.4%) were in all groups before serum for the GBV-C test was taken (1530 the main risk factors in our patients (table 1) .
{ 1403 days, 1490 { 1224 days, and 1302 { 1132 days,
Implication of GBV-C viremia and anti -E2 antibody preva-
respectively; difference not significant). Mean survival time in lence. No significant differences were found in means of aminotransferases (aspartate aminotransferase, alanine aminothe GBV-C RNA -positive group of HIV patients was 4590 { -E2 antibody -positive, GBV-C RNA -negative), and no evidence of GBV-C infection (anti -E2 antibody -negative, GBV-C RNA -negative). Nos. of surviving patients were as follows: 25 (89%) of 28 in the GBV-C -viremic patients, 71 (68%) of 104 in exposed patients, and 24 (51%) of 47 in unexposed patients. Survival time was calculated from date of first positive HIV test (available for 179 patients). HIV infection was of equal duration in all groups before serum for GBV-C serology was taken. Survival difference is statistically significant; P õ .001 (log-rank test).
279 days (95% confidence interval [CI], 4043 -5137) compared group corresponds to that of volunteer blood donors reported by others [4, 7, 8] . with 3239 { 143 days (95% CI, 2959 -3519) in the anti -E2 antibody -positive group (P Å .031, log-rank test) and with Major transmission risk factors for infection with GBV-C were intravenous drug use and homosexuality. In view of the 2591 { 217 days (95% CI, 2165 -3017) in the unexposed patients (P õ .001, log-rank test). The Kaplan-Meier survival report by Persico et al. [13] , who demonstrated the presence of GBV-C RNA in cell-free seminal plasma, the high prevaanalysis is illustrated in figure 1 .
In the absence of detailed information about acquisition of lence of GBV-C RNA in homosexuals in our study is understandable. GBV-C infection, we additionally analyzed the mean survival beginning from the date when serum was taken for analysis of In some studies, HBV and HCV infection were demonstrated to worsen the clinical course and the outcome of HIV-infected the GBV-C status. For these calculations, all 197 HIV-positive patients could be considered. Twenty-nine (87.9%) of 33 GBVpatients [1, 2] . We found no hepatitis (as measured by increased transaminases) associated with GBV-C infection in the immu-C RNA-positive patients had survived beyond the cutoff date compared with 77 (68.8%) of 112 anti-E2 antibody-positive nocompromised patients. Mean levels of transaminases, slightly above the upper normal range, did not differ between patients and with 29 (55.8%) of 52 patients without exposure to GBV-C. Mean survival of the GBV-C RNA-positive patients patients with CDC stage I, II, or III of HIV infection, indicating the same degree of liver damage in all three CDC stages. was 1052 { 42 days (95% CI, 970-1134) versus 930 { 42 days (95% CI, 847-1013) in the antibody-positive group (P Å .041, Of interest, GBV-C -viremic patients had distinctly higher CD4 cell counts and progressed less frequently to CDC stage log-rank test) and versus 777 { 67 days (95% CI, 646-909) in the unexposed group of patients (P Å .002, log-rank test).
III compared with exposed and unexposed patients. However, HIV infections were of approximately equal duration in all A Cox proportional-hazard regression model indicated that GBV-C RNA (hazard ratio, 0.22; P Å .007) is an independent subgroups up to the time when samples were taken for GBV-C serology. Kaplan-Meier analysis indicated significantly better factor associated with a relative benefit on survival more distinctly than the presence of the anti -E2 antibody (hazard ratio, cumulative survival after the first positive HIV test in the GBV-C -viremic patients (figure 1). Although GBV-C RNA -posi-0.52; P Å .017). Age of ú36 years as well as HBV infection were associated with relative risks of death (hazard ratio, 2.68; tive patients were significantly younger than antibody-positive patients, they were about the same age as the unexposed pa-P Å .006 and hazard ratio, 2.26; P Å .029, respectively). Gender and HCV antibody status had no prognostic value for the tients. A multivariable Cox regression analysis confirmed that GBV-C viremia was associated with a relative benefit on surpatients studied.
vival in the HIV-infected patients independent of other variables such as age. However, the number of GBV-C RNADiscussion positive HIV-infected patients in our study (n Å 33) is relatively small, and these results need confirmation in larger studWe found a significantly increased GBV-C RNA prevalence in the HIV-infected patients compared with the control group ies. Analyses of sequential samples might help to elucidate whether GBV-C and HIV are simultaneously acquired by blood donors (16.8% vs. 0.8%). The prevalence in our control
